Mostrar el registro sencillo del ítem

dc.contributor.advisorBustos Cruz, Rosa Helena
dc.contributor.advisorOliveros, Henry
dc.contributor.authorArias González, Milton Eduardo
dc.date.accessioned2022-04-01T13:45:12Z
dc.date.available2022-04-01T13:45:12Z
dc.date.issued2021-11-11
dc.identifier.urihttp://hdl.handle.net/10818/50269
dc.description31 páginases_CO
dc.description.abstractThis scoping review aimed to evaluate the available evidence of the use of Biologics as treat-ment candidates for the treatment of severe and advanced COVID–19 disease; what are the ra-tionale for their use, which are the most studied, and what kind of efficacy measures are de-scribed. A search through Cochrane, Embase, Pubmed, Medline, medrxiv.org and Google schol-ar was performed, on the use of biologic interventions in the COVID–19/ SARS-COV-2 infection, viral pneumonia, and sepsis, until July 31, 2021. Throughout the research, we identified 4260 records of which 84 were selected for qualitative analysis. Amongst the results, we identified 5 popular targets of use: IL6 and IL1 inhibitors, Janus Kinase inhibitors, interferons, and mesen-chymal stem cells treatment. None of them offered conclusive evidence of their efficacy with consistency and statistical significance; however, Il6 and IL1 inhibitors, as well as interferons show encouraging data in terms of increased survival and favorable clinical course that require further studies with better methodology standardization.en
dc.formatapplication/pdfes_CO
dc.language.isospaes_CO
dc.publisherUniversidad de La Sabanaes_CO
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad de La Sabanaes_CO
dc.sourceIntellectum Repositorio Universidad de La Sabanaes_CO
dc.titleBiologics in covid 19 so far “scoping review”es_CO
dc.typebachelor thesises_CO
dc.identifier.local284975
dc.identifier.localTE11625
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsopenAccesses_CO
dc.identifier.doi10.3390/xxxxx
dc.subject.armarcCOVID-19es_CO
dc.subject.armarcProductos biológicoses_CO
dc.subject.armarcBiofarmacéuticaes_CO
dc.subject.armarcInterferónes_CO
dc.subject.armarcCélulas madre mesenquimaleses_CO
thesis.degree.disciplineFacultad de Medicinaes_CO
thesis.degree.levelEspecialización en Farmacología Clínicaes_CO
thesis.degree.nameEspecialista en Farmacología Clínicaes_CO


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 InternacionalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional